公开(公告)号：US20120064639A1

公开(公告)日：2012-03-15

申请号：US13320476

申请日：2010-05-11

Applicant: Gabriel Lopez ,  Gregory Kaduchak

Inventor： Gabriel Lopez ,  Gregory Kaduchak

IPC: G01N29/02

CPC classification number: C08L83/04 ,  A61K9/0009 ,  A61K9/1641 ,  A61K9/1682 ,  A61K47/34 ,  A61K49/225 ,  G01N33/538 ,  G01N33/54313

Abstract: We describe methods for synthesis and formulations of stable elastomeric negative acoustic contrast particles with controllable compressibility and density. These elastomeric negative acoustic contrast particles have a density/compressibility ratio that is less than that of water and therefore exhibit negative acoustic contrast under acoustic radiation exposure. This negative acoustic contrast allows our elastomeric negative acoustic contrast particles to be acoustically manipulated (e.g. separated) differently from other components (e.g. cells) within an aqueous solution. This disclosure also describes methods for biofunctionalization of the elastomeric negative acoustic contrast particles and as an example their use as platforms for bioassays. Potential applications of these elastomeric negative acoustic contrast particles include sensitive bioassays based on acoustic flow cytometry and other types of techniques that utilize acoustic fields, including ultrasound imaging and ultrasound triggered drug delivery.

Abstract translation: 我们描述了具有可压缩性和密度的稳定的弹性体负型声学造影颗粒的合成方法和配方。 这些弹性体负声学对比颗粒的密度/压缩比小于水的密度/压缩比，因此在声辐射暴露下呈现负的声学对比度。 这种负声学对比度允许我们的弹性体负声学对比粒子与水溶液中的其它组分（例如细胞）不同地被声学操纵（例如分离）。 本公开还描述了弹性体负声学对比粒子的生物功能化的方法，并且作为其用作生物测定平台的实例。 这些弹性体负声学对比粒子的潜在应用包括基于声流式细胞术的敏感生物测定和利用声场的其他类型的技术，包括超声成像和超声触发药物递送。

公开(公告)号：US08134141B2

公开(公告)日：2012-03-13

申请号：US11695429

申请日：2007-04-02

Applicant: Sanjay Krishna ,  J. Scott Tyo ,  Majeed M. Hayat ,  Sunil Raghavan ,  Unal Sakoglu

Inventor： Sanjay Krishna ,  J. Scott Tyo ,  Majeed M. Hayat ,  Sunil Raghavan ,  Unal Sakoglu

IPC: H01L31/0304

CPC classification number: H01L27/14649 ,  B82Y10/00 ,  G01J3/2803 ,  G01J3/2823 ,  G01J3/32

Abstract: A semiconductor detector has a tunable spectral response. These detectors may be used with processing techniques that permit the creation of “synthetic” sensors that have spectral responses that are beyond the spectral responses attainable by the underlying detectors. For example, the processing techniques may permit continuous and independent tuning of both the center wavelength and the spectral resolution of the synthesized spectral response. Other processing techniques can also generate responses that are matched to specific target signatures.

Abstract translation: 半导体检测器具有可调谐的光谱响应。 这些检测器可以与处理技术一起使用，这些处理技术允许创建具有超过下层检测器可获得的光谱响应的光谱响应的“合成”传感器。 例如，处理技术可以允许中心波长和合成光谱响应的光谱分辨率的连续且独立的调谐。 其他处理技术也可以产生与特定目标签名匹配的响应。

公开(公告)号：US08030108B1

公开(公告)日：2011-10-04

申请号：US12492265

申请日：2009-06-26

Applicant: Seung Chang Lee ,  Steven R. J. Brueck

Inventor： Seung Chang Lee ,  Steven R. J. Brueck

IPC: H01L21/00

CPC classification number: H01L21/02603 ,  B82Y10/00 ,  B82Y40/00 ,  B82Y99/00 ,  H01L21/0237 ,  H01L21/02439 ,  H01L21/02507 ,  H01L21/02521 ,  H01L21/02639 ,  H01L29/0665 ,  H01L29/0673 ,  H01L29/127 ,  H01L29/158 ,  H01L29/7783 ,  H01L29/7853 ,  H01L33/06 ,  H01L33/18 ,  H01S5/32 ,  Y10S977/951 ,  Y10S977/962

Abstract: Exemplary embodiments provide semiconductor nanowires and nanowire devices/applications and methods for their formation. In embodiments, in-plane nanowires can be epitaxially grown on a patterned substrate, which are more favorable than vertical ones for device processing and three-dimensional (3D) integrated circuits. In embodiments, the in-plane nanowire can be formed by selective epitaxy utilizing lateral overgrowth and faceting of an epilayer initially grown in a one-dimensional (1D) nanoscale opening. In embodiments, optical, electrical, and thermal connections can be established and controlled between the nanowire, the substrate, and additional electrical or optical components for better device and system performance.

Abstract translation: 示例性实施例提供用于其形成的半导体纳米线和纳米线器件/应用和方法。 在实施例中，平面内纳米线可以在图案化衬底上外延生长，其比用于器件处理和三维（3D）集成电路的垂直纳米线更有利。 在实施方案中，可以通过使用最初在一维（1D）纳米尺度开口中生长的外延层的横向过生长和刻面的选择性外延来形成平面内纳米线。 在实施例中，可以在纳米线，衬底和附加电气或光学部件之间建立和控制光学，电气和热连接，以获得更好的器件和系统性能。

公开(公告)号：US20110218220A1

公开(公告)日：2011-09-08

申请号：US12674188

申请日：2008-08-20

Applicant: Graham Timmins ,  Sharon Master ,  Vojo P. Deretic ,  William Bishai

Inventor： Graham Timmins ,  Sharon Master ,  Vojo P. Deretic ,  William Bishai

IPC: A61K31/4409 ,  C07D213/83 ,  C07D213/81 ,  C07D213/86 ,  A61P31/06

CPC classification number: C07D213/81 ,  A61K9/0019 ,  A61K9/0073 ,  A61K31/44 ,  A61K31/4409 ,  C07D213/83 ,  C07D213/86

Abstract: The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including Mycobacterium tuberculosis.

Abstract translation: 本发明涉及异烟肼，乙硫异烟胺和相关化合物的同位素标记衍生物在治疗分枝杆菌疾病（包括结核分枝杆菌）中的有效疗法。

公开(公告)号：US07978403B2

公开(公告)日：2011-07-12

申请号：US12117334

申请日：2008-05-08

Applicant: Steven R. J. Brueck ,  Alexander Neumann ,  Yuliya V. Kuznetsova

Inventor： Steven R. J. Brueck ,  Alexander Neumann ,  Yuliya V. Kuznetsova

IPC: G02B21/00

CPC classification number: G02B21/18 ,  G02B21/06 ,  G02B21/367

Abstract: Exemplary embodiments provide an image interferometric microscope (IIM) and methods for image interferometric microscopy. The disclosed IIM can approach the linear systems limits of optical resolution by using a plurality of off-axis illuminations to access high spatial frequencies along with interferometric reintroduction of a zero-order reference beam on the low-NA side of the optical system. In some embodiments, a thin object can be placed normal to the optical axis and the frequency space limit can be extended to about [(1+NA)n/λ], where NA is the numerical-aperture of the objective lens used, n is the refraction index of the transmission medium and λ is an optical wavelength. In other embodiments, tilting the object plane can further allow collection of diffraction information up to the material transmission bandpass limited spatial frequency of about 2n/λ.

Abstract translation: 示例性实施例提供图像干涉显微镜（IIM）和用于图像干涉显微镜的方法。 所公开的IIM可以通过使用多个离轴照明来接近高分辨率的光学系统的光学分辨率的线性系统极限，以及在光学系统的低NA侧上的零级参考光束的干涉重新引入。 在一些实施例中，薄物体可以垂直于光轴放置，并且频率空间极限可以扩展到约[（1 + NA）n /λ]，其中NA是所用物镜的数值孔径，n 是传输介质的折射率，λ是光波长。 在其他实施例中，倾斜物平面可以进一步允许将衍射信息收集到材料透射带通限制空间频率约2n /λ。

公开(公告)号：US07960692B2

公开(公告)日：2011-06-14

申请号：US11753455

申请日：2007-05-24

Applicant: Gareth S. Dobson ,  Christie G. Enke

Inventor： Gareth S. Dobson ,  Christie G. Enke

IPC: H01J49/26 ,  H01J49/40

CPC classification number: H01J49/4225 ,  H01J49/0013

Abstract: A miniature linear ion trap (MLIT) with a length of less than 30 mm is provided for ion focusing in the axial plane. The MLIT has multipoles for applying an AC voltage to ions and tubular entrance and exit lenses for applying a DC voltage to the ions. In another aspect, MLIT includes electrodes within the tubular entrance and exit lenses for detection of image current. A method is also provided for applying voltage to the entrance and exit lenses for ion focusing.

Abstract translation: 提供长度小于30毫米的微型线性离子阱（MLIT）用于轴向平面中的离子聚焦。 MLIT具有用于向离子施加AC电压的多极和用于向离子施加DC电压的管状入口和出口透镜。 在另一方面，MLIT包括用于检测图像电流的管状入口和出射透镜内的电极。 还提供了一种用于向入射和离开透镜施加电压用于离子聚焦的方法。

公开(公告)号：US20110104203A1

公开(公告)日：2011-05-05

申请号：US12943709

申请日：2010-11-10

Applicant: David S. PEABODY ,  Bryce Chackerian

Inventor： David S. PEABODY ,  Bryce Chackerian

IPC: A61K39/21 ,  C07H21/04 ,  C40B50/06 ,  C40B30/00 ,  C12P21/00 ,  A61K39/12 ,  A61P31/18 ,  A61P31/12

CPC classification number: C12N15/1037 ,  A61K2039/5256 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2795/18123 ,  C40B40/02

Abstract: The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.

Abstract translation: 本发明涉及RNA噬菌体的病毒样颗粒（VLP），其（a）包含通过插入在所述VLP上显示的异源肽修饰的所述噬菌体的外壳多肽，和（b）还包封所述噬菌体mRNA 作为这些VLP的群体及其用途。 本发明还涉及包裹异源物质的VLP以及这些VLP的群体及其用途。

公开(公告)号：USRE42249E1

公开(公告)日：2011-03-29

申请号：US12217114

申请日：2008-07-01

Applicant: Gabriel P. Lopez ,  Steven R. J. Brueck ,  Linnea K. Ista

Inventor： Gabriel P. Lopez ,  Steven R. J. Brueck ,  Linnea K. Ista

IPC: B01D21/00

CPC classification number: G01N27/44773 ,  B82Y30/00 ,  G01N30/00 ,  G01N30/88 ,  G01N2030/8813 ,  Y10S977/717 ,  Y10S977/845 ,  Y10T436/25375 ,  Y10T436/255

Abstract: The present invention provides a nonostructured device comprising a substrate including nanotroughs therein; and a lipid bilayer suspended on or supported in the substrate. A separation method is also provided comprising the steps of supporting or suspending a lipid bilayer on a substrate; wherein the subtrate comprises nanostructures and wherein the lipid bilayer comprises at least one membrane associated biomolecule; and applying a driving force to the lipid bilayer to separate the membrane associated biomolecule from the lipid bilayer and to drive the membrane associated biomolecule into the nanostructures. A fluidic device for separating particles according to size is provided including a fluidic channel, and a matrix comprising a plurality of protrusions within the fluidic channel, wherein the device provides a driving force to the particles being separated through the fluidic channel; and wherein a flow of the driving force from between the protrusions is divided unequally into a major flow component and a minor flow component, each component flowing between subsequent protrusions in the matrix, such that the average direction of the major flow component is not parallel to the average direction of the driving force, and, when particles are introduced into the matrix, particles having a size less than a predetermined critical size are transported generally in the average direction of the driving force, and particles having a size at least that of the critical size are transported generally in the average direction of the major flow component, thereby separating the particles according to size. Methods for separating particles including steps of separation based on size and affinity are also provided.

Abstract translation: 本发明提供一种非结构化装置，其包括其中包括纳入通道的基板; 和悬浮在或支撑在基底中的脂质双层。 还提供了一种分离方法，包括以下步骤：在基质上支持或悬浮脂质双层; 其中所述缓冲液包含纳米结构，并且其中所述脂质双层包含至少一个膜相关的生物分子; 并将驱动力施加到脂质双层以将膜相关生物分子与脂质双层分离并将膜相关联的生物分子驱动到纳米结构中。 提供了一种用于根据尺寸分离颗粒的流体装置，包括流体通道和在流体通道内包括多个突起的基体，其中该装置为通过流体通道分离的颗粒提供驱动力; 并且其中来自所述突起之间的驱动力的流动不均匀地分成主流动分量和小流动分量，每个分量在所述基体中的后续突起之间流动，使得主流动分量的平均方向不平行于 驱动力的平均方向，并且当颗粒被引入到基质中时，尺寸小于预定临界尺寸的颗粒通常沿驱动力的平均方向传送，并且尺寸至少大于 临界尺寸通常沿主流体组分的平均方向输送，从而根据尺寸分离颗粒。 还提供了基于尺寸和亲和力分离包括分离步骤的颗粒的方法。

公开(公告)号：US07906275B2

公开(公告)日：2011-03-15

申请号：US11849126

申请日：2007-08-31

Applicant: Steven R. J. Brueck ,  Andrew Frauenglass ,  Alexander K. Raub ,  Dong Li

Inventor： Steven R. J. Brueck ,  Andrew Frauenglass ,  Alexander K. Raub ,  Dong Li

IPC: G03F7/26

CPC classification number: H01L21/3086 ,  H01L21/0337 ,  H01L21/0338 ,  H01L21/3088 ,  H01L21/31144

Abstract: In accordance with the invention, there are methods for self-aligned spatial frequency doubling in one dimension and also in two dimension. The method for self-aligned spatial frequency doubling in one dimension can include forming a film stack over a substrate, wherein the film stack comprises a photoresist layer and forming a one-dimensional periodic first pattern having a first pitch p on the photoresist layer using an optical exposure, wherein the first pitch p is at least smaller than twice the bandpass limit for optical exposures. The method can also include forming a second pattern using the first pattern by nonlinear processing steps, wherein the second pattern has a second pitch p2=p/2.

Abstract translation: 根据本发明，在一维和二维中存在自对准空间倍频的方法。 在一个维度中自对准空间倍频的方法可以包括在衬底上形成膜堆叠，其中膜堆叠包括光致抗蚀剂层并且在光刻胶层上形成具有第一间距p的一维周期性第一图案，使用 光学曝光，其中第一间距p至少小于光学曝光的带通极限的两倍。 该方法还可以包括通过非线性处理步骤使用第一图案形成第二图案，其中第二图案具有第二间距p2 = p / 2。

公开(公告)号：US07875721B2

公开(公告)日：2011-01-25

申请号：US11497751

申请日：2006-08-02

Applicant: Eric R. Prossnitz ,  Sergey E. Tkatchenko ,  Chetana M. Revankar ,  Larry A. Sklar ,  Jeffrey B. Arterburn ,  Daniel F. Cimino ,  Tudor I. Oprea ,  Cristian-George Bologa ,  Bruce S. Edwards ,  Alexander Kiselyov ,  Susan M. Young

Inventor： Eric R. Prossnitz ,  Sergey E. Tkatchenko ,  Chetana M. Revankar ,  Larry A. Sklar ,  Jeffrey B. Arterburn ,  Daniel F. Cimino ,  Tudor I. Oprea ,  Cristian-George Bologa ,  Bruce S. Edwards ,  Alexander Kiselyov ,  Susan M. Young

IPC: A61K31/435 ,  C07D221/06

CPC classification number: C07D221/16 ,  C07D405/04 ,  C07D405/14

Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

Abstract translation: 本发明在分子生物学/药理学领域，并提供调节GPR30以及经典雌激素受体α和β（ERα和ER和bgr）的作用的化合物。 这些化合物可以作为一种或多种所公开的雌激素受体的激动剂和/或拮抗剂。 通过这些受体中的一种或多种介导的疾病包括癌症（特别是乳腺，生殖和其他激素依赖性癌症，白血病，结肠癌，前列腺癌），生殖（泌尿系）包括子宫内膜炎，前列腺炎，多囊卵巢综合征，膀胱 控制，激素相关疾病，听觉障碍，心血管疾病，包括潮热和大量出汗，高血压，中风，肥胖，骨质疏松症，血液病，血管疾病或诸如静脉血栓形成，动脉粥样硬化等疾病，以及许多其他疾病和中枢和 周围神经系统，包括抑郁症，失眠，焦虑，多发性硬化，神经病变，神经变性疾病如帕金森病和阿尔茨海默病，以及炎性肠病，克罗恩病，腹腔（腹腔）疾病和肠道相关疾病。 用于预防或减少性交后怀孕的可能性的避孕指示是本发明的另一方面。